In the experiments conducted by Martin et al. [23], mice were implanted with cells from bladder cancer, melanoma or breast cancer, and then treated with anti-PD-1 as a single agent, or with combination of anti-PD-1 and anti-TGF-β. This evidence concerns the gene TGFB1 and breast carcinoma.